These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22139030)

  • 21. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
    Saif MW
    World J Gastroenterol; 2009 Aug; 15(31):3855-64. PubMed ID: 19701965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.
    Reddy SK; Broadwater G; Niedzwiecki D; Barbas AS; Hurwitz HI; Bendell JC; Morse MA; Clary BM
    J Gastrointest Surg; 2009 Jan; 13(1):74-84. PubMed ID: 18685900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
    Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
    BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatectomy for Colorectal Cancer Liver Metastases in the Era of Modern Preoperative Chemotherapy: Evaluation of Postoperative Complications.
    Fukuoka K; Nara S; Honma Y; Kishi Y; Esaki M; Shimada K
    World J Surg; 2017 Apr; 41(4):1073-1081. PubMed ID: 27679508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
    Kishi Y; Zorzi D; Contreras CM; Maru DM; Kopetz S; Ribero D; Motta M; Ravarino N; Risio M; Curley SA; Abdalla EK; Capussotti L; Vauthey JN
    Ann Surg Oncol; 2010 Nov; 17(11):2870-6. PubMed ID: 20567921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
    Lubezky N; Winograd E; Papoulas M; Lahat G; Shacham-Shmueli E; Geva R; Nakache R; Klausner J; Ben-Haim M
    J Gastrointest Surg; 2013 Mar; 17(3):527-32. PubMed ID: 23299220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
    Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
    Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients.
    Millet G; Truant S; Leteurtre E; Hebbar M; Zerbib P; Huet G; Boleslawski E; Pruvot FR
    Ann Surg; 2012 Nov; 256(5):755-61; discussion 761-2. PubMed ID: 23095619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
    Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM
    J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
    Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
    Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
    Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J
    Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
    Pessaux P; Panaro F; Casnedi S; Zeca I; Marzano E; Bachellier P; Jaeck D; Chenard MP
    Eur J Surg Oncol; 2010 Jun; 36(6):575-82. PubMed ID: 20452168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
    Oki E; Emi Y; Yamanaka T; Uetake H; Muro K; Takahashi T; Nagasaka T; Hatano E; Ojima H; Manaka D; Kusumoto T; Katayose Y; Fujiwara T; Yoshida K; Unno M; Hyodo I; Tomita N; Sugihara K; Maehara Y
    Br J Cancer; 2019 Jul; 121(3):222-229. PubMed ID: 31285591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
    Krieger PM; Tamandl D; Herberger B; Faybik P; Fleischmann E; Maresch J; Gruenberger T
    Ann Surg Oncol; 2011 Jun; 18(6):1644-50. PubMed ID: 21207168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative bevacizumab and volumetric recovery after resection of colorectal liver metastases.
    Margonis GA; Buettner S; Andreatos N; Sasaki K; Pour MZ; Deshwar A; Wang J; Ghasebeh MA; Damaskos C; Rezaee N; Pawlik TM; Wolfgang CL; Kamel IR; Weiss MJ
    J Surg Oncol; 2017 Dec; 116(8):1150-1158. PubMed ID: 28743167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
    Blazer DG; Kishi Y; Maru DM; Kopetz S; Chun YS; Overman MJ; Fogelman D; Eng C; Chang DZ; Wang H; Zorzi D; Ribero D; Ellis LM; Glover KY; Wolff RA; Curley SA; Abdalla EK; Vauthey JN
    J Clin Oncol; 2008 Nov; 26(33):5344-51. PubMed ID: 18936472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.
    Mahfud M; Breitenstein S; El-Badry AM; Puhan M; Rickenbacher A; Samaras P; Pessaux P; Lopez-Ben S; Jaeck D; Figueras J; Alain-Clavien P
    World J Surg; 2010 Jan; 34(1):92-100. PubMed ID: 19838754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
    Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
    Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
    Garufi C; Torsello A; Tumolo S; Ettorre GM; Zeuli M; Campanella C; Vennarecci G; Mottolese M; Sperduti I; Cognetti F
    Br J Cancer; 2010 Nov; 103(10):1542-7. PubMed ID: 20959822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.